Drugs / GEn-1124
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07185113 | Oct → Nov 2025 | — | GEn1E Lifesciences | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05795465 | Apr 2023 → Oct 2026 expected | acute respiratory distress syndrome | GEn1E Lifesciences | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GEn-1124 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05795465 ↗ |
| Route | Intravenous | “Intravenous infusion” NCT05795465 ↗ |